QIAGEN Accelerates Adoption of Molecular Testing for Life Sciences and Molecular Diagnostics Companies with Launch of Custom Solutions Business

OCT 30 2017

Trusted QIAGEN partners can now increase their speed to market by leveraging the company’s industry expertise, world-class manufacturing and thousands of product formulations

Beverly, Mass., October 30, 2017 – QIAGEN today announced the launch of its Custom Solutions business, extending its commitment to providing life sciences and molecular diagnostics companies with the tools and expertise required to quickly build and commercialize products that meet unique workflow requirements. QIAGEN’s new business integrates a sizable business scale, dozens of long-standing partnerships into a strong, integrated unit that offers custom and OEM sample technologies, oligo and enzyme product options for PCR, qPCR and next-generation sequencing (NGS) product development as well as a broad range of other platform technologies.

Due to recent advances in genomic sciences and precision medicine, companies are faced with increasing customer demand for more flexible, scalable and affordable molecular biology products. In their efforts to keep pace with technology innovation, many life sciences and molecular diagnostic companies face significant barriers to entry defined by the investment and time needed to develop a new product. QIAGEN Custom Solutions enables companies to overcome those challenges by providing a number of important benefits to its customers:

  • Deep domain expertise – The company has more than 30 years of life science and diagnostic industry experience.
  • Longstanding history as an OEM supplier of choice for molecular solutions – the OEM franchise at QIAGEN is a substantial part of our overall business and spans dozens of deep and long standing partnerships.
  • Thousands of flexible product capabilities – Expansive high-quality product options that directly support product development, ranging from single components to full workflow solutions, including product kitting and packaging
  • World-class facilities and quality systems – Four production sites, GMP and ISO certifications, excellent process control and QC/QA capabilities
  • Affordability and scalability – Cost-effective options that significantly lower the barrier to entry for start-ups and provide economy of scale to large enterprises
  • Continuous innovation and reinvestment –approximately 10 percent of its sales have been reinvested in R&D that helps support the new Custom Solutions business, the success of this reinvestment is evidenced by more than 2,000 patents awarded to QIAGEN.
  • Confidentiality – A series of well-established firewalls protect partner confidentiality, ensuring no leakage outside the OEM franchise.

“QIAGEN is proud to serve as an enabler to life science and molecular diagnostics companies to allow them to build high-quality custom products that meet the most demanding workflow requirements,” said Hans Peter Fatscher, Ph.D., vice president and head of QIAGEN Custom Solutions. “We are excited by the opportunity to be able to work with customers as they grow their businesses. We look forward to being their partner for innovative product development and their commercial success.”

To learn more about QIAGEN Custom Solutions visit www.qiagen.com/us/products/custom-solutions/

About QIAGEN

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA), a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharma and biotech companies) and Academia (life sciences research). As of June 30, 2017, QIAGEN employed approximately 4,600 people in over 35 locations worldwide. Further information can be found at http://www.QIAGEN.com.